Cusp-overlap technique simplifies the implantation of Chinese domestic transcatheter valve in transcatheter aortic valve implantation

摘要

Currently, transcatheter aortic valve implantation (TAVI) has become a feasible interventional technique for severe aortic stenosis in patients who deemed inoperable or are at high surgical risk. In China, the TAVI technique started from 2010. Until now two domestic devices J Valve (Jie Cheng Medical Technologies, Suzhou, China) and Venus A-Valve (Venus MedTech, Hangzhou, China) have been allowed access into the market in 2017, since then most centers began to set up TAVI programs. Venus A-Valve is the only transfemoral transcatheter valve in China which approximately has been implanted 4000 times, till VitaFlow (MicroPort, Shanghai, China) and SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) entered the market in China a few months ago.